{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:40:32Z","timestamp":1760337632349,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.annonc.2021.03.209","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T12:23:04Z","timestamp":1617798184000},"page":"825-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Building bridges between drug development and cancer science: a\u00a0tribute to Jos\u00e9 Baselga's legacy"],"prefix":"10.1016","volume":"32","author":[{"given":"D.M.","family":"Hyman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.03.209_bib1","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","article-title":"Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule","volume":"23","author":"Baselga","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","article-title":"Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"14","author":"Baselga","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib3","first-page":"5944","article-title":"Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer","volume":"9","author":"Bianchi","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2021.03.209_bib4","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1200\/JCO.1998.16.8.2659","article-title":"Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2\/neu monoclonal antibody plus cisplatin in patients with HER2\/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment","volume":"16","author":"Pegram","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.209_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.03.209_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.209_bib8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","article-title":"Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy","volume":"28","author":"Baselga","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","article-title":"Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Cort\u00e9s","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.2009.24.1661","volume":"28","author":"Gianni","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1470-2045(13)70130-X","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study","volume":"14","author":"Swain","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib12","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib14","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.2014.56.3809","article-title":"Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer","volume":"32","author":"Saura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib15","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.209_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2021.03.209_bib17","doi-asserted-by":"crossref","first-page":"283ra251","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annonc.2021.03.209_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.03.209_bib19","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1126\/science.aah6893","article-title":"PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D","volume":"355","author":"Toska","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.annonc.2021.03.209_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.annonc.2021.03.209_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jnci\/djt026","article-title":"Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2","volume":"105","author":"Gnant","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2021.03.209_bib22","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/2159-8290.CD-16-1080","article-title":"Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors","volume":"7","author":"Juric","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2021.03.209_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study","volume":"36","author":"Juric","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","article-title":"Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study","volume":"4","author":"Diamond","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.annonc.2021.03.209_bib27","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.73.0143","article-title":"AKT inhibition in solid tumors with AKT1 mutations","volume":"35","author":"Hyman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.03.209_bib28","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.drudis.2015.08.005","article-title":"Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials","volume":"20","author":"Hyman","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.annonc.2021.03.209_bib29","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2021.03.209_bib30","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jama.2017.11137","article-title":"Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing","volume":"318","author":"Mandelker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2021.03.209_bib31","doi-asserted-by":"crossref","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-04-0870","article-title":"Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting","volume":"10","author":"Matar","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421011194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:03:43Z","timestamp":1760335423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421011194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0923753421011194"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.209","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building bridges between drug development and cancer science: a\u00a0tribute to Jos\u00e9 Baselga's legacy","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.03.209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}